Keywords: AstraZeca, Motavizumab, RSV, Financial charge, Withdraws BLA, USA
AstraZeneca takes $445 million charges as it pulls RSV drug candidate motavizumab as prophylactic
Article | 21 December 2010
Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has discontinued further development of motavizumab for the prophylaxis of serious respiratory ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
